Zelquistinel

Zelquistinel
Above: Zelquistinel structure Below: 3D representation of a zelquistinel molecule
Clinical data
Routes of
administration
By mouth
Drug classNMDA receptor positive allosteric modulator
Pharmacokinetic data
Bioavailability~100%
Elimination half-life1.2–2 hours
Identifiers
  • tert-butyl (4S)-2-[(2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl]-3-oxo-2,5-diazaspiro[3.4]octane-5-carboxylate
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC15H25N3O5
Molar mass327.381 g·mol−1
3D model (JSmol)
  • C[C@H]([C@@H](C(=O)N)N1C[C@]2(C1=O)CCCN2C(=O)OC(C)(C)C)O
  • InChI=1S/C15H25N3O5/c1-9(19)10(11(16)20)17-8-15(12(17)21)6-5-7-18(15)13(22)23-14(2,3)4/h9-10,19H,5-8H2,1-4H3,(H2,16,20)/t9-,10+,15+/m1/s1
  • Key:ABAPCYNTEPGBNJ-FTGAXOIBSA-N

Zelquistinel (GATE-251, formerly AGN-241751) is an orally active small-molecule NMDA receptor positive allosteric modulator which is under development for the treatment of major depressive disorder (MDD) by Syndeio Biosciences, and previously by Allergan.